The BCR-ABL inhibitor imatinib is standard first-line therapy for patients with chronic myeloid leukemia (CML) and has revolutionized treatment of the disease. However, resistance and intolerance to the agent have emerged as major clinical complications. Dasatinib is the first and only dual BCR-ABL/SRC family kinase inhibitor approved by the U.S. Food and Drug Administration for the treatment of patients with CML in any phase or Philadelphia chromosome-positive acute lymphoblastic leukemia who are resistant to or intolerant of imatinib. The agent is well tolerated and has shown clinical activity in such patients. As with other oral tyrosine kinase inhibitors, nonadherence to the prescribed dasatinib treatment regimen could obstruct a successful outcome. A new recommended dose of 100 mg once daily has been approved for patients with chronic phase CML. That dosing regimen, combined with appropriate management of dasatinib-related adverse events, may help patients adhere to their prescribed treatment and achieve maximum therapeutic benefit. This article highlights recent changes to the dasatinib label, including results with the 100 mg once-daily starting dose for patients with chronic phase CML, and discusses nursing strategies for the successful management of adverse events in patients receiving dasatinib.
A Once-Daily Dasatinib Dosing Strategy for Chronic Myeloid Leukemia
At a Glance F Imatinib, a first-line treatment for chronic myeloid leukemia (CML), is associated with resistance and intolerance, necessitating second-line treatment options.
A new 100 mg once-daily dose of dasatinib, the first avail- (Jemal et al., 2007) . CML is characterized by the abnormal multiplication of one or more lines of bone marrow cells, including myelocytic, erythroblastic, and megakaryocytic cells (Sawyers, 1999) . The disease follows a triphasic course consisting of a relatively benign chronic phase (CP); a transitional, accelerated phase (AP); and the rapidly fatal blast phase (BP) (Sawyers). Progression from CP to BP usually occurs within three to five years if the disease is untreated (Sawyers).
The underlying molecular lesion of CML is the product of the Philadelphia chromosome (Ph), an aberration that results from the exchange of genetic material between the BCR and ABL genes on chromosomes 9 and 22, respectively. The resulting new chromosome produces a BCR-ABL fusion protein that causes development and progression of CML (Faderl et al., 1999; Sawyers, 1999) . Imatinib (Gleevec ® , Novartis Oncology) was the first BCR-ABL-targeted treatment for CML (Druker et al., 1996) . As a result of its impressive activity and relatively mild toxicity profile compared to previous treatment options, such as interferon alpha and cytarabine, imatinib has become the standard first-line therapy for CP CML and has revolutionized the treatment of the disease (Soverini, Martinelli, Iacobucci, & Baccarani, 2008) . Nonetheless, the therapeutic breakthrough with tyrosine kinases does not represent a curative strategy for CML. That would require the selective destruction of mutated stem cells, a therapeutic modality that currently remains elusive. Despite significant improvements in the physical function, wellbeing, and quality of life of patients with CML treated with imatinib (Hahn et al., 2003) , resistance and intolerance to this agent have emerged as substantial clinical issues (Ramirez & DiPersio, 2008) . In the pivotal phase III Immediate Risk-Stratification
